Pallium Canada may determine that disclosed potential or actual conflicts contravene the principles and goals set forth for LEAP curriculum and may disallow delivery of the materials. This decision will be relayed to the facilitator and organization in writing prior to the planned LEAP delivery dates.
Select one:
I intend to make therapeutic recommendations for medications that have not received regulatory approval (ie. “off-label” use of medications). (You MUST declare all off-label use to the audience during your presentation).
Pallium Canada requires LEAP presentations to be consistent in their use of either generic names, trade names or both generic and trade names during their presentation. Pallium Canada encourages facilitators and associate facilitators to use generic names whenever possible. A trade name may be used to provide participants with an example.
*Several medications or treatments currently considered best practice and/or supported by evidence in Palliative Care are “off-label” use. These are included in the LEAP courseware. Facilitators are to report these to participants when they are referred to.
Program date